Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study of Olaparib for BRCAness Phenotype in Pancreatic Cancer

Summary

The purpose of this phase II study is to determine the safety of olaparib and whether it can help to control metastatic pancreatic cancer in patients who are germline BRCA 1 or 2 negative and have a family history of breast, ovarian, pancreatic, gastric or prostate cancer in 2 or more first-degree relatives. Biomarker testing to determine if patient is eligible for the trial must be completed prior to screening for the trial.

General Information

NCT#: NCT02677038
Study ID: 2015-0503
Trial Phase: Phase II

Trial Sponsor: AstraZeneca, M.D. Anderson Cancer Center
Therapies Used in This Trial: Olaparib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search